RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @StephenVLiu: Blood based NGS is complementary to tissue. In BFAST, 25% of pts did not have tissue ALK+ (lack of tissue/testing or negat…
RT @StephenVLiu: Blood based NGS is complementary to tissue. In BFAST, 25% of pts did not have tissue ALK+ (lack of tissue/testing or negat…
RT @StephenVLiu: Blood based NGS is complementary to tissue. In BFAST, 25% of pts did not have tissue ALK+ (lack of tissue/testing or negat…
RT @StephenVLiu: Blood based NGS is complementary to tissue. In BFAST, 25% of pts did not have tissue ALK+ (lack of tissue/testing or negat…
RT @StephenVLiu: Blood based NGS is complementary to tissue. In BFAST, 25% of pts did not have tissue ALK+ (lack of tissue/testing or negat…
Blood based NGS is complementary to tissue. In BFAST, 25% of pts did not have tissue ALK+ (lack of tissue/testing or negative local test). My practice is to incorporate BOTH tissue and plasma and I've not regretted that practice (recall NILE study below) h
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer https://t.co/GUkqovIlF6
Interesting non-inferiority NILE study of tissue vs cfDNA for molecular testing in advanced NSCLC in @CCR_AACR Only 18% of patients had complete tissue genotyping but unfortunately tissue acquisition techniques and metastatic burden not described https:
RT @duemed: On using cfDNA analysis to identify biomarkers in mNSCLC. More evidence in favor of NGS @CCR_AACR https://t.co/ef7R88VEXH http…
RT @duemed: On using cfDNA analysis to identify biomarkers in mNSCLC. More evidence in favor of NGS @CCR_AACR https://t.co/ef7R88VEXH http…
RT @duemed: On using cfDNA analysis to identify biomarkers in mNSCLC. More evidence in favor of NGS @CCR_AACR https://t.co/ef7R88VEXH http…
RT @duemed: On using cfDNA analysis to identify biomarkers in mNSCLC. More evidence in favor of NGS @CCR_AACR https://t.co/ef7R88VEXH http…
RT @duemed: On using cfDNA analysis to identify biomarkers in mNSCLC. More evidence in favor of NGS @CCR_AACR https://t.co/ef7R88VEXH http…
@isliquidbiopsy @OncoAlert
RT @duemed: On using cfDNA analysis to identify biomarkers in mNSCLC. More evidence in favor of NGS @CCR_AACR https://t.co/ef7R88VEXH http…
On using cfDNA analysis to identify biomarkers in mNSCLC. More evidence in favor of NGS @CCR_AACR https://t.co/ef7R88VEXH https://t.co/SfvLpT5LLF
Real news in #precisionmedicine: #patients with #lungcancer may be able to avoid repeat biopsy re insufficient sample for biomarker testing. Safer, evidence-based care for more people! https://t.co/P1j14tcW0s
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer https://t.co/GdOwgvsS7Y
Are we on the edge of paradigm shift in molecular testing? @AACR NILE Study: head-to-head trial finds liquid biopsy is as effective as tissue testing in detecting #NSCLC #lungcancer biomarkers #precisionmedicine BTW-love the study name being from Egypt
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer https://t.co/1VA6gozKVG
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @mtmdphd: Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metas…
Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer [Apr 15, 2019] Leighl et al @CCR_AACR https://t.co/fm6suTwyLM @GuardantHealth #PrecisionMedicine
Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer [Apr 15, 2019] Leighl et al. @CCR_AACR https://t.co/fm6suTwyLM @GuardantHealth #PrecisionMedicin
RT @Kamacintosh: Strong concordance and faster results than tissue for EGFR, ALK, ROS1, BRAF in blood / quicker diagnosis, earlier targeted…
RT @Kamacintosh: Strong concordance and faster results than tissue for EGFR, ALK, ROS1, BRAF in blood / quicker diagnosis, earlier targeted…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @Kamacintosh: Strong concordance and faster results than tissue for EGFR, ALK, ROS1, BRAF in blood / quicker diagnosis, earlier targeted…
RT @Kamacintosh: Strong concordance and faster results than tissue for EGFR, ALK, ROS1, BRAF in blood / quicker diagnosis, earlier targeted…
Strong concordance and faster results than tissue for EGFR, ALK, ROS1, BRAF in blood / quicker diagnosis, earlier targeted therapy starts #lcsm #lungcancer #biomarkers
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @susanahprieto: Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer https://t.co/l6ukxQNpH2
RT @susanahprieto: Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer https://t.co/EnTBnwXP3T
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @Kamacintosh: Liquid Biopsy / Biomarkers #lcsm #lungcancer https://t.co/8avsgdLKZp
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @Kamacintosh: Liquid Biopsy / Biomarkers #lcsm #lungcancer https://t.co/8avsgdLKZp
RT @Kamacintosh: Liquid Biopsy / Biomarkers #lcsm #lungcancer https://t.co/8avsgdLKZp
Liquid Biopsy / Biomarkers #lcsm #lungcancer
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
RT @BrendonStilesMD: More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and f…
More compelling evidence that a blood draw may be all you need to genotype your lung cancer. Strong concordance and faster results than tissue for EGFR, ALK, ROS1, BRAF in blood cfDNA - from https://t.co/Fm6fpavrTu #lcsm https://t.co/PpnRhJ5ruo
Clinical Utility of Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer https://t.co/q27IGWonYx the blood-first diagnostic paradigm in the metastatic setting has (finally) arrived @Gu
Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer https://t.co/Ip7Png5stG